youtube.com
Oct 31, 2024, 12:50
Andrea Necchi: Phase I (TEM-GU) study is recruiting patients with metastatic clear cell renal carcinoma
Andrea Necchi, Associate Editor at Journal of Clinical Oncology, posted the following on X:
“Happy to share this innovative phase I (TEM-GU) study is now active and recruiting patients with metastatic clear cell RCC who have a disease progressing after at least 2 lines of treatment including IO and a VEGF-TKI.
Temferon is a gene therapy with hematopoietic stem cells designed to reprogram the tumor microenvironment by delivering immunomodulatory molecules directly to tumors.”
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Dec 21, 2024, 12:18
Dec 21, 2024, 11:52
Dec 21, 2024, 11:30
Dec 21, 2024, 11:25
Dec 21, 2024, 11:18